With demonstrating proof-of-concept of FAP-tPDT on SSc patient-derived fibroblasts, we have obtained the first functional in vitro evidence that supports the further development of this innovative technique for treatment of SSc. This evidence concerns the gene FAP and systemic sclerosis.